title: The RNA-binding protein HuR regulates DNA methylation through stabilization of DNMT3b mRNA.
abstract: The molecular basis underlying the aberrant DNA-methylation patterns in human cancer is largely unknown. Altered DNA methyltransferase (DNMT) activity is believed to contribute, as DNMT expression levels increase during tumorigenesis. Here, we present evidence that the expression of DNMT3b is post-transcriptionally regulated by HuR, an RNA-binding protein that stabilizes and/or modulates the translation of target mRNAs. The presence of a putative HuR-recognition motif in the DNMT3b 3'UTR prompted studies to investigate if this transcript associated with HuR. The interaction between HuR and DNMT3b mRNA was studied by immunoprecipitation of endogenous HuR ribonucleoprotein complexes followed by RT-qPCR detection of DNMT3b mRNA, and by in vitro pulldown of biotinylated DNMT3b RNAs followed by western blotting detection of HuR. These studies revealed that binding of HuR stabilized the DNMT3b mRNA and increased DNMT3b expression. Unexpectedly, cisplatin treatment triggered the dissociation of the [HuR-DNMT3b mRNA] complex, in turn promoting DNMT3b mRNA decay, decreasing DNMT3b abundance, and lowering the methylation of repeated sequences and global DNA methylation. In summary, our data identify DNMT3b mRNA as a novel HuR target, present evidence that HuR affects DNMT3b expression levels post-transcriptionally, and reveal the functional consequences of the HuR-regulated DNMT3b upon DNA methylation patterns.
authors.affiliation: Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain. ilsilanes@cnio.es
authors.forename: Isabel
authors.initials: I
authors.lastname: López de Silanes
authors.forename: Myriam
authors.initials: M
authors.lastname: Gorospe
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Taniguchi
authors.forename: Kotb
authors.initials: K
authors.lastname: Abdelmohsen
authors.forename: Subramanya
authors.initials: S
authors.lastname: Srikantan
authors.forename: Miguel
authors.initials: M
authors.lastname: Alaminos
authors.forename: María
authors.initials: M
authors.lastname: Berdasco
authors.forename: Rocío G
authors.initials: RG
authors.lastname: Urdinguio
authors.forename: Mario F
authors.initials: MF
authors.lastname: Fraga
authors.forename: Filipe V
authors.initials: FV
authors.lastname: Jacinto
authors.forename: Manel
authors.initials: M
authors.lastname: Esteller
mesh_terms: D000954:Antigens, Surface / Q000032:analysis / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology; D001483:Base Sequence; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000235:genetics* / Q000378:metabolism; D019175:DNA Methylation; D051959:ELAV Proteins; D000067780:ELAV-Like Protein 1; D006801:Humans; D008969:Molecular Sequence Data; D020871:RNA Stability; D012333:RNA, Messenger / Q000378:metabolism*; D016601:RNA-Binding Proteins / Q000032:analysis / Q000378:metabolism*; D000097584:DNA Methyltransferase 3B
chemical_list: D000954:Antigens, Surface; D000970:Antineoplastic Agents; D002945:Cisplatin; D004248:DNA (Cytosine-5-)-Methyltransferases; D051959:ELAV Proteins; D000067780:ELAV-Like Protein 1; D012333:RNA, Messenger; D016601:RNA-Binding Proteins; D000097584:DNA Methyltransferase 3B; C098770:ELAVL1 protein, human